참고문헌
- Beierwaltes WH, Rabbani R, Dmuchowski C, et al (1984). An analysis of ''ablation of thyroid remnants'' with I-131 in 511 patients from 1947-1984: experience at University of Michigan. J Nucl Med, 25, 1287-93.
- Budak A, GulhanI, Aldemir OS, et al (2013). Lack of influence of pregnancy on the prognosis of survivors of thyroid cancer. Asian Pac J Cancer Prev, 14, 6941-43. https://doi.org/10.7314/APJCP.2013.14.11.6941
- Cooper D, Doherty G, Haugen B, et al (2009). Revised American thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid, 19, 1167-214. https://doi.org/10.1089/thy.2009.0110
- Edwards B, Howe H, Ries L, et al (2002). Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on US cancer burden. Cancer, 94, 2766-92. https://doi.org/10.1002/cncr.10593
- Giovanella L, Ceriani L, Ghelfo A, Keller F (2005). Thyroglobulin assay 4 weeks after thyroidectomy predicts outcome in lowrisk papillary thyroid carcinoma. Clin Chem Lab Med, 43, 843-47.
- Hyo L, Rha Y, Suk Jo Y, et al (2007). Predictive value of the preablation serum thyroglobulin level after thyroidectomy is combined with postablation 131I whole body scintigraphy for successful ablation in patients with differentiated thyroid carcinoma. Am J Clin Oncol, 30, 63-8. https://doi.org/10.1097/01.coc.0000239138.64949.0a
- Hussain Z, Zaman U, Malik S, et al (2014). Preablation stimulated thyroglobulin/TSH ratio as a predictor of successful I131remnant ablation in patients with differentiated thyroid cancer following total thyroidectomy. J Thyroid Res.
- Iyer NG, Morris LG, Tuttle RM, et al (2011). Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy. Cancer, 117, 4439-46. https://doi.org/10.1002/cncr.26070
- Karam M, Gianoukakis A, Feustel PJ, et al (2003). Influence of diagnostic and therapeutic doses on thyroid remnant ablation rates. Nucl Med Commun, 24, 489-95. https://doi.org/10.1097/00006231-200305000-00002
- Kim TY, Kim WB, Kim ES, et al (2005). Serum thyroglobulin levels at the time of 131I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab, 90, 1440-45. https://doi.org/10.1210/jc.2004-1771
- Lin Y, Li T, Liang J, et al (2011). Predictive value of preablation stimulated thyroglobulin and thyroglobulin/thyroidstimulating hormone ratio in differentiated thyroid cancer. Clinical Nuclear Medicine, 36, 1102-05. https://doi.org/10.1097/RLU.0b013e3182291c65
- Lim I, Kim S, Hwang S, Kim SW, et al (2012). Prognostic implication of thyroglobulin and quantified whole body scan after initial radioiodine therapy on early prediction of ablation and clinical response for the patients with differentiated thyroid cancer. Ann Nucl Med, 26, 777-86. https://doi.org/10.1007/s12149-012-0640-1
- Mazzaferri EL, Kloos RT (2001). Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab, 86, 1447-63. https://doi.org/10.1210/jcem.86.4.7407
- Mazzaferri E, Robbins R, Spencer C, et al (2003). A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab, 88, 1433-41. https://doi.org/10.1210/jc.2002-021702
- Mallick U, Harmer C, Yap B, et al (2012). Ablation with lowdose radioiodine and thyrotropin alfa in thyroid cancer. N Engl J Med, 366, 1674-85. https://doi.org/10.1056/NEJMoa1109589
- Robbins R, Schlumberger M (2005). The evolving role of I-13I for the treatment of differentiated thyroid carcinoma. J Nucl Med, 46, 28-37.
- Pacini F, Capezzone M, Elisei R, et al (2002). Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment. J Clin Endocrinol Metab, 87, 1499-501. https://doi.org/10.1210/jcem.87.4.8274
- Pacini F, Schlumberger M, Dralle H, et al (2006). European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Europ Jourl of Endo, 154, 787-803. https://doi.org/10.1530/eje.1.02158
- Rosario PW, Reis JS, Barroso AL, et al (2004). Efficacy of low and high I-131 doses for thyroid remnant ablation in patients with differentiated thyroid carcinoma based on postoperative cervical uptake. Nucl Med Commun, 25, 1077-81. https://doi.org/10.1097/00006231-200411000-00002
- Schlumberger M. (1998). Papillary and follicular thyroid carcinoma. N Engl J Med, 338, 297-306. https://doi.org/10.1056/NEJM199801293380506
- Souza R, Barroso A, Rezende L, et al (2004). Post I-131 therapy scanning in patients with thyroid carcinoma metastases: an unnecessary cost or a relevant contribution? Clin Nucl Med, 29, 795-98. https://doi.org/10.1097/00003072-200412000-00005
- Sritara C, Charoenphun P, Ponglikitmongkol M, et al (2012). Serum oncofetal fibronectin (onfFN) mRNA in differentiated thyroid carcinoma (DTC): large overlap between diseasefree and metastatic oatients. Asian Pac J Cancer Prev, 13, 4203-08. https://doi.org/10.7314/APJCP.2012.13.8.4203
- Schlumberger M, Catargi B, Borget I, et al (2012). Strategies of radioiodine ablation in patients with low-risk thyroid cancer. N Engl J Med, 366, 1663-73. https://doi.org/10.1056/NEJMoa1108586
- Vaisman F, Shaha A, Fish S, et al (2001). Initial therapy with either thyroid lobectomy or total thyroidectomy without radioactive iodine remnant ablation is associated with very low rates of structural disease recurrence in properly selected patients with differentiated thyroid cancer. Clinical Endocrinology, 75, 112-9.
- Verburg F, deKeizer B, Lips C, et al (2005). Prognostic significance of successful ablation with radioiodine of differentiated thyroid cancer patients. Eur J Endocrinol, 152, 33-37. https://doi.org/10.1530/eje.1.01819
- Zaman M, Fatima N, Padhy AK, Zaman U (2013). Controversies about radioactive iodine-131 remnant ablation in low risk thyroid cancers: are we near a consensus? Asian Pac J Cancer Prev, 14, 6209-13. https://doi.org/10.7314/APJCP.2013.14.11.6209
피인용 문헌
- Comparable Ablation Efficiency of 30 and 100 mCi of I-131 for Low to Intermediate Risk Thyroid Cancers Using Triple Negative Criteria vol.17, pp.3, 2016, https://doi.org/10.7314/APJCP.2016.17.3.1115
- The predictive value for excellent response to initial therapy in differentiated thyroid cancer vol.39, pp.5, 2018, https://doi.org/10.1097/MNM.0000000000000827